Figure EV5. Anti‐BTNL2 mAb aggravates DSS‐induced colitis in mice.

• A–C
  Body weight changes (A), representative colon image (left) and colon length (right) (B), and representative histological images (C) of wild‐type mice treated with Isotype rat IgG1 control Ab or anti‐BTNL2 mAb (ip. 200 μg/mouse) at day 0, 2, 4, and 6 during DSS treatment were shown (n = 6). Data information: All data are mean ± s.e.m. **P < 0.01, ***P < 0.001 based on two‐way ANOVA for (A) and two‐tailed Student's t‐test for (B). Each dot represents one repetition, n = 6.
• D
  Summary schematic. BTNL2 acts on Group 3 innate lymphoid cells (ILC3s), CD4⁺ T cells, and γδ T cells in the gut to produce IL‐22 through JAK‐STAT3‐HIF‐1α/RORC pathway, and a monoclonal antibody blocking BTNL2 attenuates colorectal tumorigenesis in mice by attenuating IL‐22 production in the gut.

Source data are available online for this figure.